HBM Healthcare Investments is a principal investment firm established in 2001 and based in Zug, Switzerland, with a focus on the biotechnology, human medicine, diagnostics, and medical technology sectors. The firm invests globally in approximately 40 mature emerging companies, primarily targeting private firms that demonstrate significant value creation potential. Approximately two-thirds of its portfolio consists of investments in unquoted companies, while the remainder includes public companies and funds. HBM Healthcare Investments has developed a distinctive market position through its strategic investments in firms whose products are either at advanced stages of development or already available in the market. This diversified approach allows the firm to leverage opportunities across Europe, Asia, and North America, contributing to its broad shareholder base and enhancing its investment capabilities.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
1000Farmacie SRL is an Italian company based in Naples that operates an online platform for retail pharmacies. The platform offers a diverse selection of products authorized for online sale, including pharmaceuticals, cosmetics, food supplements, and pet care items, all bearing the CE guarantee mark. By facilitating the purchase of healthcare products from authorized pharmacies, 1000Farmacie enables customers to obtain these items at competitive prices. The company also provides a same-day delivery service to specified locations, enhancing convenience for its users and allowing them to save both time and money.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines.
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.
Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
ValCare, Inc. is a medical device company established in 2012 and headquartered in Irvine, California. The company specializes in the design and development of devices and accessories aimed at the minimally invasive treatment of heart valve disease, specifically targeting conditions such as mitral and tricuspid regurgitation. ValCare's innovative technology functions as a docking station for replacement prostheses and provides tools for mitral annulus repair, facilitating advanced treatment options for patients with heart disorders. This approach aims to enhance patient recovery times and improve overall health outcomes.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.
Farmalisto is an online pharmacy that connects healthcare providers with users, facilitating the purchase of medications, particularly for chronic and complex conditions. Founded in 2013 and based in Bogotá, Colombia, with operations in Mexico City, the platform offers a diverse range of products, including pharmaceuticals, personal care items, and baby hygiene products. Additionally, Farmalisto provides logistics, marketing, and disease management services to pharmaceutical companies, enhancing access to healthcare solutions. Its services include home assistance and laboratory support, ensuring that patients can receive necessary medications and care within the comfort of their homes or offices.
MicroOptx, Inc. is a medical device company based in Maple Grove, Minnesota, founded in 2014. It specializes in developing innovative solutions for the treatment of glaucoma, focusing on minimizing intraocular pressure to prevent blindness. The company's flagship product, the Beacon Aqueous Microshunt (BAM), effectively shunts aqueous humor from the anterior chamber to the surface of the eye. Additionally, MicroOptx produces SalVO, a minimally invasive glaucoma surgery micro implant designed for veterinary use. By combining expertise in bioengineering, surgical techniques, and advanced manufacturing, MicroOptx aims to transform glaucoma treatment through its platform technology. The company is committed to addressing this progressive disease, guided by a leadership team with extensive experience in the medical and financial sectors.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, specializing in monoclonal antibody therapies aimed at treating sepsis and related conditions. Founded in 2009, the company focuses on developing its lead product candidate, Adrecizumab, a first-in-class humanized monoclonal antibody that targets Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. Adrecizumab is designed to address life-threatening situations characterized by increased vascular leakage, congestion, and shock, with primary indications including sepsis, septic shock, and acute heart failure. Adrenomed's innovative approach integrates its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker to identify suitable patients for treatment. The company boasts a robust intellectual property portfolio, with patents granted in major markets, securing its business position in the competitive biopharmaceutical landscape.
Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.
Sphingotec GmbH is a biopharmaceutical company based in Brandenburg, Germany, founded in 2002. The company specializes in the development of biomarkers aimed at diagnosing, predicting, and monitoring acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec focuses on creating monoclonal antibody therapies combined with targeted diagnostic tests tailored for critically ill patients. These innovations work to neutralize harmful substances in the bloodstream, normalize organ function, and enhance survival rates. Additionally, Sphingotec offers biomarkers that assess kidney and endothelial function in critical conditions, thereby enabling healthcare professionals to improve patient management and accelerate recovery for those with severe health issues.
BaseHealth, Inc. is a health management platform designed for physicians and their patients, integrating genomic, medical, behavioral, and environmental data to evaluate disease risks. The platform aids physicians in formulating personalized action plans aimed at disease prevention. It serves as a clinical support tool, enhancing medical decision-making by combining physician expertise, clinical knowledge, genome interpretation, and health analytics. Additionally, BaseHealth provides tailored recommendations regarding diet and physical activity based on individual health conditions and genetic profiles. Founded in 2008, the company is headquartered in Sunnyvale, California, and operates as a subsidiary of Genalyte, Inc. The platform employs machine learning to analyze extensive medical literature and patient records, enabling healthcare providers to identify patients at risk for 43 chronic diseases, ultimately aiming to reduce the need for costly treatments.
Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.
Shape Memory Medical is a medical device company based in Santa Clara, California, established in 2009. The company specializes in the commercialization of innovative medical devices that utilize shape memory polymer (SMP) materials, originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical targets the peripheral vascular, cardiovascular, and neurovascular markets, focusing on minimally invasive endovascular applications. The company has introduced the first FDA-cleared medical device in the vascular sector that employs SMP technology, enhancing the ability of physicians to deliver improved patient care. With a team experienced in SMP foam technology and medical device commercialization, Shape Memory Medical aims to provide advanced therapeutic solutions in its field.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Amphora Medical, Inc. is a Minnesota-based company that develops medical devices focused on treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is working on a novel cystoscopic device designed to enhance bladder function and improve the quality of life for patients suffering from OAB. Utilizing minimally invasive procedures and advanced cystoscopic technology, Amphora Medical aims to provide effective solutions for individuals affected by this condition.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.
Vascular Dynamics, Inc. is a privately-held company founded in 2008, specializing in the development and commercialization of innovative medical devices for the treatment of drug-resistant hypertension. The company offers the MobiusHD, a catheter-delivered implant designed to enhance the natural baroreceptor response in the carotid sinus. This minimally invasive procedure aims to stimulate vasodilation, reduce heart rate, modulate kidney response, and ultimately decrease blood pressure. Originally established by Rainbow Medical Ltd., Vascular Dynamics has a team with over 75 years of combined experience in the medical device field. The company is based in Irvine, California, with prior development and commercialization activities conducted in Mountain View, California.
Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products.
AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine).
AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products.
AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Mpex Pharmaceuticals is a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, with a particular focus on gram-negative organisms. The Company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).
MiCardia is a privately held medical device company currently preparing for the commercialization of its first series of products, enCor™, in the European Union. enCor is a unique device that surgically treats mitral valve regurgitation. enCor utilizes the company's patented technology, Dynaplasty™, to provide a "second chance" to the patient who develops recurrent regurgitation. enCor can be activated to physiologically adjust the mitral valve leaflets to resolve regurgitation, minimally invasively, weeks to years later, without the need for the risk and cost of redo surgery.
Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions.
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
MiCardia is a privately held medical device company currently preparing for the commercialization of its first series of products, enCor™, in the European Union. enCor is a unique device that surgically treats mitral valve regurgitation. enCor utilizes the company's patented technology, Dynaplasty™, to provide a "second chance" to the patient who develops recurrent regurgitation. enCor can be activated to physiologically adjust the mitral valve leaflets to resolve regurgitation, minimally invasively, weeks to years later, without the need for the risk and cost of redo surgery.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions.
Mpex Pharmaceuticals is a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, with a particular focus on gram-negative organisms. The Company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.
ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors.
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).
Thommen Medical is a medical device company that specializes in the development, production, and sale of dental implants branded as SPI (Swiss Precision Implant). The company focuses on creating innovative and precisely designed implant systems that enhance patient comfort during surgical procedures and ensure long-term stability of the implants. Thommen Medical also offers biomaterial solutions for bone and tissue regeneration, collaborating with leading scientific and dental clinicians to improve the effectiveness and usability of its products. Through its commitment to design excellence and innovation, Thommen Medical aims to achieve optimal success for its clients in the field of dental implants.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Triage Medical
Series B in 2003
Triage Medical Inc., an Irvine, Calif.-based developer orthopedic trauma devices.
New Medical Technologies
Acquisition in 2003
New Medical Technologies Management provides investment opportunities for all sectors of the emerging medical technology industries.
Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.